NEW DATA SERVICE
Patient, Endocrinologist, Primary Care Experiences and Expectations with GLP-1s & SGLT-2s
True trended insights, from both patients and HCPs, to bring clarity to your decision making
New Data and Insights Available
Data and Insights from:
- 3,500 fully-validated current, former and potential GLP-1 and SGLT-2 patients (Ozempic; Mounjaro; Wegovy; Trulicity; Victoza; Rybelsus; Jardiance; Farxiga; Invokana)
- dQ&A’s 2022 and 2023 national surveys of Endocrinologists and Primary Care Physicians
- Qualitative Endocrinologist and PCP interviews
- Five year drug class and brand trends, updated every 90 days
- Patient Satisfaction and NPS trended from 2016 to today
Answers to key questions about:
- HCP prescribing trends and intentions
- Endocrinologist and Primary Care reasons to prescribe
- Patient expectations and experiences
- ‘Patient Pull’ vs. ‘Prescriber Push’
- Patient Reasons for switching and quitting
- Patient Future Intentions
Options for:
- Custom reports, dataset pulls and analysis
- Follow-up custom questions and surveys
- Qualitative deep dives from our expert team
- Presentations and discussions about the implications for your business.
Available Now:
with regular updates throughout 2024